{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:45:51Z","timestamp":1782859551760,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2026.06.007","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:57:34Z","timestamp":1782856654000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT"],"prefix":"10.1016","author":[{"given":"Moein","family":"Moradpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5519-6982","authenticated-orcid":false,"given":"Chae Moon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abuzar Moradi","family":"Tochayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surekha","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2228-5823","authenticated-orcid":false,"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.06.007_b0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.007_b0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (Vision): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.06.007_b0015","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1007\/s00259-024-06718-6","article-title":"Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer","volume":"51","author":"Song","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.06.007_b0020","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2967\/jnumed.124.267955","article-title":"Impact of posttreatment SPECT\/CT on patient management during 177Lu-PSMA-617 radiopharmaceutical therapy","volume":"65","author":"Yadav","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2026.06.007_b0025","article-title":"Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv","volume":"15","author":"Emmett","year":"2023","journal-title":"Med Oncol"},{"key":"10.1016\/j.euo.2026.06.007_b0030","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2967\/jnumed.125.269495","article-title":"Randomized Phase 2 trial of an extended and flexible dosing schedule of 177Lu-PSMA molecular radiotherapy in patients with metastatic castration-resistant prostate cancer (FLEX-MRT): study protocol","volume":"66","author":"Holzgreve","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2026.06.007_b0035","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.007_b0040","article-title":"SPECT\/CT in early response assessment of patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617","volume":"65","author":"Demirci","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2026.06.007_b0045","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.euo.2026.01.008","article-title":"Radiographic progression without prostate-specific antigen progression in metastatic hormone-sensitive prostate cancer: A retrospective analysis of the ENZAMET trial (ANZUP 1304)","volume":"9","author":"Inderjeeth","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.06.007_b0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.euo.2024.04.009","article-title":"Radiographic progression without corresponding prostate-specific antigen progression in patients with metastatic castration-sensitive prostate cancer receiving apalutamide: secondary analysis of the Titan trial","volume":"8","author":"Fukuokaya","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.06.007_b0055","article-title":"Prognostic value of initial imaging and PSA change with [177Lu]Lu-PSMA-617 radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer: a ProsTIC registry analysis","volume":"66","author":"Chen","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2026.06.007_b0060","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2967\/jnumed.125.269640","article-title":"Prognostic value of posttherapy SPECT\/CT for overall survival in patients undergoing [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: results from 3 clinical trials","volume":"66","author":"Kashyap","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2026.06.007_b0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2967\/jnumed.122.264398","article-title":"Evaluation of 177Lu-PSMA-617 SPECT\/CT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)","volume":"64","author":"Pathmanandavel","year":"2023","journal-title":"J Nucl Med"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:57:35Z","timestamp":1782856655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"alternative-id":["S2588931126001756"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.007","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}